|Bid||18.43 x 1000|
|Ask||18.72 x 800|
|Day's Range||18.47 - 19.64|
|52 Week Range||12.02 - 19.82|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.60|
-- Advanced Oncology Pipeline with FSI-189, an Anti-SIRPα Antibody; Investigational New Drug (IND) Application-Enabling Studies Expected to Begin in 2019 –-- New England Journal.
MENLO PARK, Calif., Nov. 07, 2018 -- Forty Seven Inc. (NASDAQ:FTSV) a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the.
-- 5F9 Priming Dose Results in CD47 Pruning, Removing CD47 from Surface of Red Blood Cells to Mitigate Risk of Anemia -- -- 5F9 Demonstrates Synergy in Combination with.
MENLO PARK, Calif., Oct. 03, 2018 -- Forty Seven Inc. (NASDAQ:FTSV) today announced the formation of its Scientific Advisory Board (SAB), comprised of four leading scientists.
The flood of local IPOs passed last year's total of 15 in July and appears well on its way to top the recent high 34 in 2014, with four more coming this week. Here's how the stocks from this year's crop of new Bay Area public companies have performed so far.
Forty Seven Inc. (NASDAQ: FTSV ) , a clinical-stage immuno-oncology companhy that went public in June, picked up two sell-side bulls Monday. The Analysts Morgan Stanley analyst Matthew Harrison initiated Forty ...